Running a nuclear power plant isn’t an easy task, even with the level of automation available to a 1980s Soviet RBMK reactor.

Ready to start your vibe-coding adventure? A few weeks after its debut on Mac, the Windows version of OpenAI’s Codex app has finally arrived.

All hail the return of the World Baseball Classic! The WBC, the sport's flagship international tournament, is about to get underway with the 2026 edition. This year, the tournament is back at four ...

Running Claude Code locally is easy. All you need is a PC with high resources. Then you can use Ollama to configure and then ...

House Minority Leader Hakeem Jeffries said he plans to attend President Donald Trump’s State of the Union, saying, “We're not going to Donald Trump's house. He's coming to our house,” and adding, “You ...

Chicago plays host to more than 4,000 miles of public streets. Joabe Bayer Barbosa has almost run them all. Barbosa, 25, has now completed more than 80 percent of Chicago’s map, according to the ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

WASHINGTON — The U.S. Senate voted Thursday to block the DC Council's decision to divorce from some of the tax breaks included in President Donald Trump's One Big Beautiful bill. The 49-47 vote ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

A federal judge in Washington has blocked the Trump administration from closing down a humanitarian program that allowed around 350,000 Haitians to live and work legally in the U.S., according to ...

OpenAI just lobbed a grenade at vibe-coding startups like Cursor and Windsurf. The company behind ChatGPT has announced the Codex MacOS app, its take on an integrated development environment (IDE) ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.